Published in Am J Ophthalmol on January 01, 2004
Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol (2010) 1.45
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence (2011) 1.17
Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol (2007) 0.99
Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol (2010) 0.96
Latanoprost in the treatment of glaucoma. Clin Ophthalmol (2014) 0.95
Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol (2007) 0.93
Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci (2011) 0.87
Compliance: clear communication's critical. Br J Ophthalmol (2005) 0.81
[Preservatives in ophthalmology]. Ophthalmologe (2012) 0.80
Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma. Clin Ophthalmol (2015) 0.79
Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clin Ophthalmol (2012) 0.78
Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol (2013) 0.77
Psychometrics of a new questionnaire to assess glaucoma adherence: the Glaucoma Treatment Compliance Assessment Tool (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2013) 0.76
Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clin Ophthalmol (2014) 0.76
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics (2012) 0.76
Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months. Ophthalmol Ther (2016) 0.76
A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. BMC Ophthalmol (2011) 0.75
Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol (2005) 2.31
Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med (2002) 2.07
Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care (2010) 1.54
Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis (2004) 1.51
Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology (2005) 1.26
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence (2011) 1.17
The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med (2011) 1.08
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol (2004) 1.06
Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care (2002) 1.05
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care (2002) 1.00
A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes (2003) 0.99
Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol (2003) 0.98
Variations in treatment among adult-onset open-angle glaucoma patients. Ophthalmology (2005) 0.94
Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol (2013) 0.93
Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol (2004) 0.91
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin (2009) 0.91
Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther (2003) 0.89
Management of hypertension and hypercholesterolaemia in primary care in The Netherlands. Curr Med Res Opin (2005) 0.87
Economic consequences of ACS-related rehospitalizations in the US. Curr Med Res Opin (2010) 0.87
Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy (2002) 0.87
Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. BMC Ophthalmol (2010) 0.85
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. Am J Health Syst Pharm (2011) 0.84
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. Curr Med Res Opin (2009) 0.82
Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care (2002) 0.82
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents (2004) 0.78
Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. J Comp Eff Res (2013) 0.78
Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Curr Med Res Opin (2007) 0.77
A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol (2004) 0.77
Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manag Care (2002) 0.76
Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy (2003) 0.75
A practice-based research network focused on comparative effectiveness research in type 2 diabetes management. Postgrad Med (2013) 0.75
Economic consequences of severe bleeding in patients with acute coronary syndrome in the USA. Adv Ther (2010) 0.75
Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther (2014) 0.75
Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy (2002) 0.75
Argon versus selective laser trabeculoplasty. J Glaucoma (2004) 0.75